HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gummy Vitamin Manufacturing Hurdles Grow With Demand For Novel Formulations

Executive Summary

Gummy manufacturing challenges include stability of “decaying” active ingredients, loading all ingredients into limited space and inadequate testing, says Church & Dwight scientist Kristen Farr.

You may also be interested in...



Traditional But Trendy: Capsules And Tablets Lead VMS Delivery Formats Despite Gummy Growth

Natural Marketing Institute survey found capsules (42%) and tablets (41%) are most popular supplement formats followed by gummies (35%). Results presented during a Council for Responsible Nutrition webinar showed younger consumers are willing to try formats such as tinctures, oral sprays and tablets.

Demand For Vitafusion, L’il Critters Gummy Lines Exceeds Church & Dwight Capacity, Drive Q3 Growth

Church & Dwight reports strong consumption of its Vitafusion and L’il Critters vitamins drove personal care product division sales up 24.5% and prompted it to use contract manufacturing to meet demand. The firm also adjusted its net sales outlook for the year to 11% and its EPS to $2.79-$2.81.

With Avid Buy, Church & Dwight Seeks Sweet Spot For Supplement Market Growth

C&D sees fragmentation of gummy vitamin market as an opening to become a “strong, agile competitor” and drive growth in a rapidly expanding category with newly acquired Avid Health’s Vitafusion and L’il Critters brands.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150825

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel